Patients treated for congestive heart failure (CHF) by noncardiologists face a greater risk of not receiving lifesaving prescription therapy for their condition, according to a new study published in the American Journal of Health- System Pharmacy.
The drugs in questionbeta-blockers, angiotensin-converting enzyme inhibitors (ACEIs), and aldosterone antagonistshave all been shown to significantly decrease morbidity and mortality, and are among the medications recommended by the Heart Failure Society of America to treat CHF, hospital pharmacy leaders explained.
But in a study examining prescribing differences by medical specialty, researchers discovered that:
Mr. Rankin is a freelance medical writer.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs